Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus HALDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus HALDRONE.
CORTONE vs HALDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Glucocorticoid receptor agonist; suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene transcription.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
Oral: Initial dose 50-100 mg twice daily; maintenance 25-50 mg twice daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Terminal elimination half-life: 2.6-3.8 hours. Clinical context: Short half-life requires multiple daily dosing; no significant accumulation with regular dosing.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Renal: 20-30% as unchanged drug; biliary/fecal: 70-80% as metabolites and unchanged drug.
Category C
Category C
Corticosteroid
Corticosteroid